标题
The current state of the art and future trends in RAS-targeted cancer therapies
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 19, Issue 10, Pages 637-655
出版商
Springer Science and Business Media LLC
发表日期
2022-08-26
DOI
10.1038/s41571-022-00671-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor.
- (2022) W. Clay Gustafson et al. JOURNAL OF CLINICAL ONCOLOGY
- First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety
- (2022) John H Strickler et al. JOURNAL OF CLINICAL ONCOLOGY
- KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.
- (2022) Tanios S. Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
- (2022) Sai-Hong Ignatius Ou et al. JOURNAL OF CLINICAL ONCOLOGY
- Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
- (2022) Victoria Hall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts
- (2022) Vania Vidimar et al. MOLECULAR CANCER THERAPEUTICS
- KRAS is vulnerable to reversible switch-II pocket engagement in cells
- (2022) James D. Vasta et al. Nature Chemical Biology
- First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.
- (2022) Shubham Pant et al. JOURNAL OF CLINICAL ONCOLOGY
- Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
- (2022) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Rise of Molecular Glues
- (2021) Stuart L. Schreiber CELL
- KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
- (2021) Joshua K. Sabari et al. JOURNAL OF CLINICAL ONCOLOGY
- MO01.32 CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
- (2021) M. Reck et al. Journal of Thoracic Oncology
- Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type
- (2021) Amin H. Nassar et al. NEW ENGLAND JOURNAL OF MEDICINE
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
- (2021) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- KRAS drives immune evasion in a genetic model of pancreatic cancer
- (2021) Irene Ischenko et al. Nature Communications
- Bispecific antibodies targeting mutant RAS neoantigens
- (2021) Jacqueline Douglass et al. Science Immunology
- 99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation
- (2021) G.J. Riely et al. Journal of Thoracic Oncology
- KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from the in vitro experiments
- (2021) Takamasa Koga et al. Journal of Thoracic Oncology
- ES28.04 Emerging Mechanisms to Target KRAS Directly
- (2021) M. Nagasaka Journal of Thoracic Oncology
- The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
- (2021) David M. Briere et al. MOLECULAR CANCER THERAPEUTICS
- Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation
- (2021) Noritaka Tanaka et al. Cancer Discovery
- LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
- (2021) J. Weiss et al. ANNALS OF ONCOLOGY
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC
- (2021) Kwan Ho Tang et al. Cancer Discovery
- PROTAC cell permeability and oral bioavailability: a journey into uncharted territory
- (2021) Vasanthanathan Poongavanam et al. Future Medicinal Chemistry
- Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
- (2021) Xiaolun Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
- (2021) Marwan G Fakih et al. LANCET ONCOLOGY
- Diverse alterations associated with resistance to KRAS(G12C) inhibition
- (2021) Yulei Zhao et al. NATURE
- The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS
- (2021) Chuanchuan Li et al. SCIENCE
- Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells
- (2021) Adelina Plangger et al. Translational Oncology
- The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
- (2021) Teklab Gebregiworgis et al. Nature Communications
- Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry
- (2021) Febe van Maldegem et al. Nature Communications
- Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
- (2021) Biagio Ricciuti et al. Journal of Thoracic Oncology
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- The small molecule BI-2852 induces a nonfunctional dimer of KRAS
- (2020) Timothy H. Tran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Frequency of Ras Mutations in Cancer
- (2020) Ian A. Prior et al. CANCER RESEARCH
- Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).
- (2020) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
- (2020) Keisuke Yamamoto et al. NATURE
- Guidelines and definitions for research on epithelial–mesenchymal transition
- (2020) Jing Yang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
- (2020) Vito Amodio et al. Cancer Discovery
- A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
- (2020) Nicolas Bery et al. Nature Communications
- An in vivo KRAS allelic series reveals distinct phenotypes of common oncogenic variants
- (2020) Maria Paz Zafra et al. Cancer Discovery
- KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
- (2020) Tatu Pantsar Scientific Reports
- Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
- (2020) Michael J. Bond et al. ACS Central Science
- Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer
- (2020) Yuta Adachi et al. CLINICAL CANCER RESEARCH
- SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
- (2020) Carmine Fedele et al. JOURNAL OF EXPERIMENTAL MEDICINE
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition
- (2020) Marco H Hofmann et al. Cancer Discovery
- GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
- (2020) Ziyang Zhang et al. ACS Central Science
- Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
- (2020) Harold J. Burstein NEW ENGLAND JOURNAL OF MEDICINE
- Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report
- (2020) Qinghan Liu et al. TUMORI
- Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States
- (2020) Shuhui Lim et al. ACS Central Science
- Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
- (2019) Roman C. Hillig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
- (2019) Conan G. Kinsey et al. NATURE MEDICINE
- CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment
- (2019) A. Tirella et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
- (2019) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
- (2019) Kevin Lou et al. Science Signaling
- Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles
- (2019) Aditi Mehta et al. PHARMACEUTICAL RESEARCH
- Drugging an undruggable pocket on KRAS
- (2019) Dirk Kessler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- RAS: Striking at the Core of the Oncogenic Circuitry
- (2019) Ryan C. Gimple et al. Frontiers in Oncology
- New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
- (2019) Haitang Yang et al. Frontiers in Oncology
- Bifunctional Small-Molecule Ligands of K-Ras Induce Its Association with Immunophilin Proteins
- (2019) Ziyang Zhang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
- (2019) Sarah Greene et al. CLINICAL CANCER RESEARCH
- A Convergence-Based Framework for Cancer Drug Resistance
- (2018) David J. Konieczkowski et al. CANCER CELL
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- The Rasopathy family: Consequences of germline activation of the RAS/MAPK pathway
- (2018) Mylène Tajan et al. ENDOCRINE REVIEWS
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
- (2018) Gabrielle S. Wong et al. NATURE MEDICINE
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
- (2018) Sara Mainardi et al. NATURE MEDICINE
- Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
- (2018) Vincent L. Cannataro et al. ONCOGENE
- Afatinib restrains K-RAS–driven lung tumorigenesis
- (2018) Herwig P. Moll et al. Science Translational Medicine
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
- (2018) Elisa Caiola et al. Scientific Reports
- Targeting the MAPK Pathway in RAS Mutant Cancers
- (2018) Sarah G. Hymowitz et al. Cold Spring Harbor Perspectives in Medicine
- Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
- (2018) Shunsuke Kitajima et al. CANCER CELL
- Regulatory mechanisms of PD-L1 expression in cancer cells
- (2018) Yongyu Shi CANCER IMMUNOLOGY IMMUNOTHERAPY
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
- (2018) Chien-Hui Weng et al. ONCOGENE
- The functional diversity of Aurora kinases: a comprehensive review
- (2018) Estelle Willems et al. Cell Division
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
- (2018) Sandra Misale et al. CLINICAL CANCER RESEARCH
- Therapeutic strategies to target RAS-mutant cancers
- (2018) Meagan B. Ryan et al. Nature Reviews Clinical Oncology
- Pharmacological targeting of RAS: Recent success with direct inhibitors
- (2018) John P. O’Bryan PHARMACOLOGICAL RESEARCH
- Exceptionally high-affinity Ras binders that remodel its effector domain
- (2017) John H. McGee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects
- (2017) Christian W. Johnson et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
- (2017) Sushrut Kamerkar et al. NATURE
- Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
- (2017) Rodrigo Romero et al. NATURE MEDICINE
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
- (2017) Zev A. Wainberg et al. Targeted Oncology
- Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d
- (2017) Satoshi Sogabe et al. ACS Medicinal Chemistry Letters
- AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer
- (2017) Ahmed S.K. Al-Khafaji et al. Oncology Letters
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- (2017) Emmet J. Jordan et al. Cancer Discovery
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
- (2017) Leanne G. Ahronian et al. Genome Medicine
- Deconstruction of the Ras switching cycle through saturation mutagenesis
- (2017) Pradeep Bandaru et al. eLife
- Sticking It to Cancer with Molecular Glue for SHP2
- (2016) Hao Ran et al. CANCER CELL
- Negative feedback regulation of the ERK1/2 MAPK pathway
- (2016) David Lake et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
- (2016) J. E. Grilley-Olson et al. INVESTIGATIONAL NEW DRUGS
- Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
- (2016) Edmilson Ozorio dos Santos et al. Molecular Cancer
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- (2016) Joshua D Campbell et al. NATURE GENETICS
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
- (2015) M. Soucheray et al. CANCER RESEARCH
- Functions of Shp2 in cancer
- (2015) Jie Zhang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition
- (2015) Pavel A. Levin et al. Journal of Thoracic Oncology
- Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas
- (2015) Helena A. Yu et al. Journal of Thoracic Oncology
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site
- (2015) Mohammad T. Mazhab-Jafari et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
- (2015) Zeynep Eroglu et al. Therapeutic Advances in Medical Oncology
- Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
- (2014) Piro Lito et al. CANCER CELL
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
- (2014) Diletta Di Mitri et al. NATURE
- Integrated RAS signaling defined by parallel NMR detection of effectors and regulators
- (2014) Matthew J Smith et al. Nature Chemical Biology
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
- (2014) S. L. Highfill et al. Science Translational Medicine
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor
- (2013) Sang Min Lim et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- CXCR2-Expressing Myeloid-Derived Suppressor Cells Are Essential to Promote Colitis-Associated Tumorigenesis
- (2013) Hiroshi Katoh et al. CANCER CELL
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
- (2012) A. B. Turke et al. CANCER RESEARCH
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- (2012) Marcin Imielinski et al. CELL
- A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
- (2012) Swarnali Acharyya et al. CELL
- Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer
- (2012) Winfried H. Alsdorf et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis
- (2012) Thomas Jamieson et al. JOURNAL OF CLINICAL INVESTIGATION
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- The genetics and biology of KRAS in lung cancer
- (2012) Peter M. K. Westcott et al. Chinese Journal of Cancer
- WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
- (2011) P. C. De Witt Hamer et al. CLINICAL CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer
- (2011) Toshiaki Watanabe et al. DISEASES OF THE COLON & RECTUM
- Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
- (2011) J. Y. Guo et al. GENES & DEVELOPMENT
- Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
- (2011) Hideaki Ijichi et al. JOURNAL OF CLINICAL INVESTIGATION
- Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice
- (2011) Leina Sun et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
- (2011) M. Cargnello et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders
- (2010) Lothar Gremer et al. HUMAN MUTATION
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
- (2009) K. Schmid et al. CLINICAL CANCER RESEARCH
- Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
- (2008) Li Yang et al. CANCER CELL
- BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins
- (2008) B. B. Friday et al. CANCER RESEARCH
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now